Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
Research output: Contribution to journal › Journal article › Research › peer-review
The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.
| Original language | English |
|---|---|
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 67 |
| Issue number | 8 |
| Pages (from-to) | 2020-8 |
| Number of pages | 9 |
| ISSN | 0305-7453 |
| DOIs | |
| Publication status | Published - 2012 |
ID: 48451514